A Multi-center Open-Label Adaptive Randomized Study of Palifosfamide-tris a Novel DNA Crosslinker in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naive Patients with Extens
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The main purpose of this study is to see if palifosfamide-tris with etoposide and carboplatin can extend the length of time that the cancer is stable and to help patients live longer, compared to treatment with etoposide and carboplatin
Description
The main purpose of this study is to see if palifosfamide-tris with etoposide and carboplatin can extend the length of time that the cancer is stable and to help patients live longer, compared to treatment with etoposide and carboplatin
Details
| Condition | Lung Cancer |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX2647 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.